A phase Ib clinical trial of EOS-448 in combination with pembrolizumab in patients with solid tumors
Latest Information Update: 06 Sep 2023
At a glance
- Drugs Belrestotug (Primary) ; Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 14 Jun 2021 According to a GlaxoSmithKline media release, the company expect to initiate this trial in 2022.
- 21 May 2021 New trial record